Diabetic wounds and various infectious skin diseases pose a significant burden on healthcare systems worldwide. To address these issues, ViaDerma (OTC: VDRM), a California-based biotech company, has developed a groundbreaking drug delivery system. ViaDerma’s transdermal drug delivery system is unparalleled in terms of effectiveness and efficiency when put side by side with other products on the market. Below, we will delve into the technology behind ViaDerma’s transdermal drug delivery system, its applications with the lead product Vitastem Ultra, and the benefits it offers to doctors and patients worldwide.
ViaDerma is developing and licensing its transdermal drug delivery system, which can deliver antibiotics and other essential drugs directly to the site of infection, bypassing the bloodstream and the need for injections or oral antibiotics. This TDD technology is beneficial for treating minor to severe diabetic wounds, which are slow to heal and prone to infection. Their unique delivery system works by applying a spray (as used with Vitastem Ultra) containing the drug onto the skin’s surface, where it is absorbed directly into the underlying tissue. ViaDerma’s TDD is designed to be painless, easy to apply, and very effective.
One of the notable advantages of ViaDerma’s transdermal drug delivery system is its speed of action. Traditional drug delivery systems rely on pills or intravenous injections, which can take hours or even days to reach the site of an infection. In contrast, ViaDerma’s transdermal drug delivery system delivers drugs within minutes, providing relief to patients faster than ever before. This rapid delivery mechanism is especially crucial for treating diabetic wounds, as early intervention is essential to prevent further complications.
Vitastem uses a patent-pending, specialized combination of ingredients, optimizing the delivery formula that allows medicine to be transmitted at 10x the strength and depth of other products in the modern marketp.
To date, ViaDerma’s lead product Vitastem Ultra has prevented countless amputations due to non-healing diabetic wounds. In fact, Vitastem Ultra boasts that 96% of patients with diabetic wounds and ulcers see improvement within just 2 weeks, surpassing the largest name-brand Rx competitor, where only 50% of patients see improvements at around 20 weeks of continuous usage.
Another significant benefit of ViaDerma’s transdermal drug delivery system is its targeted delivery. Traditional drug delivery systems, like pills or injections, can distribute drugs throughout the body, leading to unwanted side effects and an increased risk of drug resistance. ViaDerma’s transdermal drug delivery system delivers drugs directly to the site of infection, ensuring that patients receive the treatment they need without unnecessary risks.
ViaDerma’s innovative TDD system also offers a more effective way of delivering antibiotics. Antibiotic resistance and the rapid increase of superbugs in healthcare facilities are significant public health concerns, necessitating alternative methods of drug delivery. ViaDerma’s solutions offer a breakthrough for delivering antibiotics, quickly delivering drugs directly to the site of infection where they are needed most. This fast targeted delivery increases the overall effectiveness of antibiotics while reducing the risks of resistance and improving patient outcomes.
ViaDerma’s highly innovative transdermal drug delivery system offers a real breakthrough solution for treating diabetic wounds and various infectious skin diseases. Its targeted delivery system, fast delivery, and superior effectiveness make it unparalleled compared to other products on the market. ViaDerma’s technology provides genuine hope for patients suffering from diabetes-related complications and various skin diseases. For doctors, it offers an effective tool for managing infections and ensuring the best possible outcomes for their patients. ViaDerma’s TDD solution for healthcare is one of the most promising breakthroughs in modern medicine.
As the company is gearing up to meet growing international demand for Vitastem Ultra with high-volume orders in The Caribbean, Egypt, The Middle East, and India, where the company expects to deliver at least 300,000 units per country in 2024 alone. As this innovative specialty pharmaceutical company continues to expand its offerings to healthcare facilities around the world, we all should look forward to seeing how ViaDerma and the lead product, Vitastem Ultra, can transform healthcare globally in the years to come.
